Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a rare, life-threatening complication that can lead to multiorgan failure and death. The ALXN1210-TMA-314 global, Phase 3, open-label, single-arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT-TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT-TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight-based ravulizumab plus best supportive care during the 26-week treatment period, followed by a 26-week follow-up period. The protocol-defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT-TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. TRIAL REGISTRATION: NCT04557735.
Authors
- Eric Scott Bachman
- David Bueno (ORCID: https://orcid.org/0000-0003-3392-3285)
- Sarah A. Lawson (ORCID: https://orcid.org/0000-0001-7395-5447)
- Franco Locatelli (ORCID: https://orcid.org/0000-0002-7976-3654)
- Jude Fry
- Michelle Long Schoettler (ORCID: https://orcid.org/0000-0003-4565-6399)
- Christopher C. Dvorak (ORCID: https://orcid.org/0000-0002-6146-3952)
- Cory Williams
- Hideki Sano (ORCID: https://orcid.org/0000-0002-3242-6917)
- Sonali Chaudhury (ORCID: https://orcid.org/0000-0001-9816-5126)
- Daiichiro Hasegawa (ORCID: https://orcid.org/0000-0003-2245-6554)
- Hyoung Jin Kang (ORCID: https://orcid.org/0000-0003-1009-6002)
- Cynthia Carrillo-Infante (ORCID: https://orcid.org/0009-0002-0654-7560)
- Yoshiyuki Takahashi (ORCID: https://orcid.org/0000-0001-8644-171X)
- Min Qin
- Aviva Krauss
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Northwestern University (US)
- National Health Service (GB)
- Lurie Children's Hospital (US)
- Seoul National University (KR)
- Emory University (US)
- University of California, San Francisco (US)
- Hospital Universitario La Paz (ES)
- Birmingham Children's Hospital (GB)
- Seoul National University Children's Hospital (KR)
- Schneider Children's Medical Center (IL)
- Bambino Gesù Children's Hospital (IT)
- Kobe Children's Hospital (JP)
- Alexion Pharmaceuticals (United States) (US)
- Fukushima Medical University Hospital (JP)
- Children's Healthcare of Atlanta (US)
- Nagoya University (JP)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1002/ajh.70545
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Alexion Pharmaceuticals